Challenges in managing amniotic fluid embolism: An up-to-date perspective on diagnostic testing with focus on novel biomarkers and avenues for future research

Current Pharmaceutical Biotechnology

Volumn 14, Issue 14, 2013, Pages 1168-1178

  Stawicki, Stanislaw P ^a   Papadimos, Thomas J ^b  

^a ST LUKE S UNIVERSITY HEALTH NETWORK   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Amniotic fluid embolism; Biomarkers; Diagnosis; Management; Proteomics; Transcriptomics

Indexed keywords

ACTIVIN A; ALPHA 2 GLOBULIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD59 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CHROMOGRANIN A; COMPLEMENT; COPROPORPHYRIN; DYNEIN ADENOSINE TRIPHOSPHATASE; ENDOTHELIN; FIBRONECTIN; INTERLEUKIN 6; KERATIN TYPE I; MEMBRANE ASSOCIATED GUANYLATE CYCLASE KINASE; MESOTHELIN; MICRORNA; PREALBUMIN; PROCOLLAGEN C PROTEINASE; PROOPIOMELANOCORTIN; PROSTATE SPECIFIC ANTIGEN; SIALOSYL TN; SOMATOMEDIN BINDING PROTEIN 1; SQUAMOUS CELL CARCINOMA ANTIGEN; SUPEROXIDE DISMUTASE; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TRYPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMNION FLUID EMBOLISM; ARTICLE; DIAGNOSTIC TEST; DISSEMINATED INTRAVASCULAR CLOTTING; DISSEMINATED INTRAVASCULAR COAGULATION MARKER; FETUS CELL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIPIDOMICS; NONHUMAN; PROTEOMICS; TRANSCRIPTOMICS; ANIMAL; EMBOLISM, AMNIOTIC FLUID; FEMALE; GENE EXPRESSION PROFILING; METABOLISM; PREGNANCY; RESEARCH;

ANIMALS; BIOLOGICAL MARKERS; EMBOLISM, AMNIOTIC FLUID; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PREGNANCY; PROTEOMICS; RESEARCH;

EID: 84904055386     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140430163921     Document Type: Article

References (128)

1. Thongrong, C.; Kasemsiri, P.; Hofmann, J. P.; Bergese, S.D.;Papadimos, T.J.; Gracias, V.H.; Adolph, M.D.;Stawicki, S.P. Amniotic fluid embolism. Int. J. Crit. Illness Injury Sci., 2013, 3(1), 51-57.
2. Abenhaim, H.A.; Azoulay, L.; Kramer, M.S.; Leduc, L. Incidence and risk factors of amniotic fluid embolisms: A population-based study on 3 million births in the United States. Amer. J. Obstet. Gynecol., 2008, 199(1), 49 e1-8.
3. Meyer, J.R. Embolia pulmonar amnio caseosa. J. Bras. Med., 1926, 2, 301-303.
4. Steiner, P.E.; Lushbaugh, C.C. Maternal pulmonary embolism by amniotic fluid. JAMA, 1941, 117, 1245-1254.
5. Kissko III J.M.; Gaiser, R., Amniotic fluid embolism. Anesthesiol. Clin., 2013, 31(3), 609-621.
6. Tsunemi, T.; Oi, H.; Sado, T.; Naruse, K.; Noguchi, T.; Kobayashi, H. An overview of amniotic fluid embolism: Past, present and future directions. Open Women's Health J., 2012, 6, 24-29.
7. Conde-Agudelo, A.; Romero, R. Amniotic fluid embolism: An evidence-based review. Amer. J. Obstet. Gynecol., 2009, 201(5), 445 e1-13.
8. Harnett, M.J.; Hepner, D.L.; Datta, S.; Kodali, B.S. Effect of amniotic fluid on coagulation and platelet function in pregnancy: an evaluation using thromboelastography. Anaesthesia, 2005, 60(11), 1068-1072.
9. Gogola, J.; Hankins, G.D. Amniotic fluid embolism in progress: A management dilemma! Amer. J. Perinatol., 1998, 15(8), 491-493.
10. Resnik, R.; Swartz, W.H.; Plumer, M.H.; Benirschke, K.; Stratthaus, M.E. Amniotic fluid embolism with survival. Obstet. Gynecol., 1976, 47(3), 295-298.
11. Lunetta, P.; Penttila, A. Immunohistochemical identification of syncytiotrophoblastic cells and megakaryocytes in pulmonary vessels in a fatal case of amniotic fluid embolism. Int. J. Legal Med., 1996, 108(4), 210-214.
12. Lee, W.; Ginsburg, K.A.; Cotton, D.B.; Kaufman, R.H. Squamous and trophoblastic cells in the maternal pulmonary circulation identified by invasive hemodynamic monitoring during the peripartum period. Amer. J. Obstet. Gynecol., 1986, 155(5), 999-1001.
13. Clark, S.L.; Pavlova, Z.; Greenspoon, J.; Horenstein, J.; Phelan, J.P. Squamous cells in the maternal pulmonary circulation. Amer. J. Obstet. Gynecol., 1986, 154(1), 104-106.
14. Sakuma, M.; Sugimura, K.; Nakamura, M.; Takahashi, T.; Kitamukai, O.; Yazu, T.; Yamada, N.; Ota, M.; Kobayashi, T.; Nakano, T.; Shirato, K. Unusual pulmonary embolism: Septic pulmonary embolism and amniotic fluid embolism. Circulat. J., 2007, 71(5), 772-775.
15. Kobayashi, H.; Naruse, K.; Sado, T.; Noguchi, T.; Yoshida, S.; Shigetomi, H.; Onogi, A.; Oi, H. Search for amniotic fluid-specific markers: Novel biomarker candidates for amniotic fluid embolism. Open Women's Health J., 2011, 5, 7-15.
16. Benson, M.D. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin. Development. Immunol., 2012, 2012, 946576.
17. Choi, D.S.; Kim, D.K.; Kim, Y.K.; Gho, Y.S. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics, 2013, 13(10-11), 1554-1571.
18. Engwegen, J.Y.; Gast, M.C.; Schellens, J.H.; Beijnen, J.H. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacologic. Sci., 2006, 27(5), 251-259.
19. Carpentier, S.C.; Panis, B.; Swennen, R.; Lammertyn, J. Finding the significant markers: statistical analysis of proteomic data. Methods Mol. Biol., 2008, 428, 327-347.
20. Morrow, D.A.; de Lemos, J.A.; Sabatine, M.S.; Antman, E.M. The search for a biomarker of cardiac ischemia. Clin. Chem., 2003, 49(4), 537-539.
21. Queloz, P.A.; Crettaz, D.; Thadikkaran, L.; Sapin, V.; Gallot, D.; Jani, J.; Deprest, J.; Lemery, D.; Barelli, S.; Tissot, J.D. Proteomic analyses of amniotic fluid: Potential applications in health and diseases. J. Chromatogr. B, 2007, 850(1-2), 336-342.
22. el Maradny, E.; Kanayama, N.; Halim, A.; Maehara, K.; Terao, T. Endothelin has a role in early pathogenesis of amniotic fluid embolism. Gynecol. Obstet. Invest., 1995, 40(1), 14-18.
23. Kobayashi, H.; Ooi, H.; Hayakawa, H.; Arai, T.; Matsuda, Y.; Gotoh, K.; Tarao, T. Histological diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc epitope. Human Pathol., 1997, 28(4), 428-433.
24. Oi, H.; Kobayashi, H.; Hirashima, Y.; Yamazaki, T.; Kobayashi, T.; Terao, T., Serological and immunohistochemical diagnosis of amniotic fluid embolism. Sem. Thrombos. Hemostas., 1998, 24(5), 479-84.
25. Hammerschmidt, D.E.; Ogburn, P.L.; Williams, J.E. Amniotic fluid activates complement. A role in amniotic fluid embolism syndrome? J. Lab. Clin. Med., 1984, 104(6), 901-917.
26. Fineschi, V.; Riezzo, I.; Cantatore, S.; Pomara, C.; Turillazzi, E.; Neri, M. Complement C3a expression and tryptase degranulation as promising histopathological tests for diagnosing fatal amniotic fluid embolism. Virchows Archiv., 2009, 454(3), 283-290.
27. Kanayama, N.; Yamazaki, T.; Naruse, H.; Sumimoto, K.; Horiuchi, K.; Terao, T. Determining zinc coproporphyrin in maternal plasma - a new method for diagnosing amniotic-fluid embolism. Clin. Chem., 1992, 38(4), 526-529.
28. Hosono, K.; Matsumura, N.; Matsuda, N.; Fujiwara, H.; Sato, Y.; Konishi, I. Successful recovery from delayed amniotic fluid embolism with prolonged cardiac resuscitation. J. Obstet. Gynaecol. Res., 2011, 37(8), 1122-1125.
29. Takeshima, N.; Suminami, Y.; Takeda, O.; Abe, H.; Kato, H. Origin of CA125 and SCC antigen in human amniotic fluid. AOFOG, 1993, 19(2), 199-204.
30. Sarandakou, A.; Kontoravdis, A.; Kontogeorgi, Z.; Rizos, D.; Phocas, I. Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy. Europ. J. Obstet., Gynecol., Reproduct. Biol., 1992, 44(3), 215-220.
31. Usta, I. M.; Sibai, B. M.; Mercer, B. M.; Kreamer, B. L.; Gourley, G.R. Use of maternal plasma level of zinc-coproporphyrin in the prediction of intrauterine passage of meconium: a pilot study. J. Maternal-Fetal Med., 2000, 9(4), 201-213.
32. Kobayashi, H.; Ohi, H.; Terao, T. A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc. Amer. J. Obstet. Gynecol., 1993, 168 3 Pt 1), 848-853.
33. Oi, H.; Naruse, K.; Noguchi, T.; Sado, T.; Kimura, S.; Kanayama, N.; Terao, T.; Kobayashi, H. Fatal factors of clinical manifestations and laboratory testing in patients with amniotic fluid embolism. Gynecol. Obstet. Inves., 2010, 70(2), 138-144.
34. Nishio, H.; Matsui, K.; Miyazaki, T.; Tamura, A.; Iwata, M.; Suzuki, K. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. Forensic Sci. Int., 2002, 126(1), 53-56.
35. Farrar, S.C.; Gherman, R.B. Serum tryptase analysis in a woman with amniotic fluid embolism. A case report. J. Reproduct. Med., 2001, 46(10), 926-928.
36. Benson, M.D.; Lindberg, R.E. Amniotic fluid embolism, anaphylaxis, and tryptase. Amer. J. Obstet. Gynecol., 1996, 175(3 Pt 1), 737.
37. Fineschi, V.; Gambassi, R.; Gherardi, M.; Turillazzi, E. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. Int. J. Legal Med., 1998, 111(5), 238-243.
38. Payne, V.; Kam, P. C. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia, 2004, 59(7), 695-703.
39. Christiansen, L. R.; Collins, K. A. Pregnancy-associated deaths: a 15-year retrospective study and overall review of maternal pathophysiology. Amer. J. Forensic Med. Pathol., 2006, 27(1), 11-19.
40. Benson, M. D., A hypothesis regarding complement activation and amniotic fluid embolism. Med. Hypotheses, 2007, 68(5), 1019-1025.
41. Williams, M.A.; Farrand, A.; Mittendorf, R.; Sorensen, T.K.; Zingheim, R.W.; O'Reilly, G.C.; King, I.B.; Zebelman, A.M.; Luthy, D.A. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Amer. J. Epidemiol., 1999, 149(4), 323-329.
42. Menon, R.; Thorsen, P.; Vogel, I.; Jacobsson, B.; Morgan, N.; Jiang, L.; Li, C.; Williams, S.M.; Fortunato, S.J. Racial disparity in amniotic fluid concentrations of tumor necrosis factor (TNF)-alpha and soluble TNF receptors in spontaneous preterm birth. Amer. J. Obstet. Gynecol., 2008, 198(5), 533 e1-10.
43. Menon, R.; Camargo, C.; Thorsen, P.; Lombardi, S.J.; Fortunato, S.J. Amniotic fluid interleukin-6 increase is an indicator of spontaneous preterm birth in white but not black Americans. Amer. J. Obstet. Gynecol., 2008, 198(1).
44. Torbe, A.; Czajka, R.; Kordek, A.; Rzepka, R.; Kwiatkowski, S.; Rudnicki, J. Maternal serum proinflammatory cytokines in preterm labor with intact membranes: neonatal outcome and histological associations. Europ. Cytokine Network, 2007, 18(2), 102-7.
45. Holst, R.M.; Laurini, R.; Jacobsson, B.; Samuelsson, E.; Savman, K.; Doverhag, C.; Wennerholm, U.B.; Hagberg, H. Expression of cytokines and chemokines in cervical and amniotic fluid: relationship to histological chorioamnionitis. J. Maternal-Fetal Neonatal Med., 2007, 20(12), 885-893.
46. Menon, R.; Williams, S.M.; Fortunato, S.J. Amniotic fluid interleukin-1beta and interleukin-8 concentrations: racial disparity in preterm birth. Reprod. Sci., 2007, 14(3), 253-259.
47. Vascotto, C.; Salzano, A.M.; D'Ambrosio, C.; Fruscalzo, A.; Marchesoni, D.; di Loreto, C.; Scaloni, A.; Tell, G.; Quadrifoglio, F. Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia. J. Proteome Res., 2007, 6(1), 160-170.
48. Naruse, K.; Taketoshi, N.; Yoshida, S.; Tsunemi, T.; Shigetomi, H.; Oi, H.; Kobayashi, H. Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers. Open J. Obstet. Gynecol., 2012, 2, 147-150.
49. Abboud, J.; Murad, Y.; Chen-Scarabelli, C.; Saravolatz, L.; Scarabelli, T.M. Peripartum cardiomyopathy: A comprehensive review. Int. J. Cardiol., 2007, 118(3), 295-303.
50. Smulian, J.C.; Vintzileos, A.M.; Lai, Y.L.; Santiago, J.; Shen-Schwarz, S.; Campbell, W.A. Maternal chorioamnionitis and umbilical vein interleukin-6 levels for identifying early neonatal sepsis. J. Maternal-Fetal Med., 1999, 8(3), 88-94.
51. Khosravi, J.; Krishna, R.G.; Bodani, U.; Diamandi, A.; Khaja, N.; Kalra, B.; Kumar, A. Immunoassay of serine-phosphorylated isoform of insulin-like growth factor (IGF) binding protein (IGFBP)-1. Clin. Biochem., 2007, 40(1-2), 86-93.
52. Van Cortenbosch, B.; Huel, C.; Houfflin Debarge, V.; Luton, D.; Lambaudie, E.; Porquet, D.; Guibourdenche, J., Biologic tests for the diagnosis of amniotic fluid embolism. Annales de Biologie Clinique., 2007, 65(2), 153-160.
53. Kingsley, D.M. The Tgf-beta superfamily - new members, new receptors, and new genetic tests of function in different organisms. Gene Dev., 1994, 8(2), 133-146.
54. Florio, P.; Cobellis, L.; Luisi, S.; Ciarmela, P.; Severi, F. M.; Bocchi, C.; Petraglia, F., Changes in inhibins and activin secretion in healthy and pathological pregnancies. Molecul. Cellul. Endocrinol., 2001, 180(1-2), 123-130.
55. O'Connor, A.E.; McFarlane, J.R.; Hayward, S.; Yohkaichiya, T.; Groome, N.P.; de Kretser, D.M., Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum. Reprod. 1999, 14(3), 827-832.
56. Jones, R.L.; Stoikos, C.; Findlay, J.K.; Salamonsen, L.A. TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction, 2006, 132(2), 217-232.
57. Florio, P.; Lambert-Messerlian, G.; Severi, F.M.; Buonocore, G.; Canick, J.A.; Petraglia, F. Fetal neural tube defects: maternal serum and amniotic fluid activin A levels. Prenatal Diagnos., 2004, 24(7), 574-575.
58. de Lemos, J.A.; Morrow, D.A. Brain natriuretic peptide measurement in acute coronary syndromes: Ready for clinical application? Circulation, 2002, 106(23), 2868-2870.
59. Yamamoto, K.; Burnett, J.C., Jr.; Jougasaki, M.; Nishimura, R.A.; Bailey, K.R.; Saito, Y.; Nakao, K.; Redfield, M.M. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension, 1996, 28(6), 988-994.
60. Furuhashi, N.; Kimura, H.; Nagae, H.; Yajima, A.; Kimura, C.; Saito, T. Brain natriuretic peptide and atrial natriuretic peptide levels in normal pregnancy and preeclampsia. Gynecol. Obstet. Invest., 1994, 38(2), 73-77.
61. Torbicki, A.; Perrier, A.; Konstantinides, S.; Agnelli, G.; Galie, N.; Pruszczyk, P.; Bengel, F.; Brady, A.J.B.; Ferreira, D.; Janssens, U.; Klepetko, W.; Mayer, E.; Remy-Jardin, M.; Bassand, J. P.; Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S. D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L.; Zamorano, J.L.; Andreotti, F.; Ascherman, M.; Athanassopoulos, G.; De Sutter, J.; Fitzmaurice, D.; Forster, T.; Heras, M.; Jondeau, G.; Kjeldsen, K.; Knuuti, J.; Lang, I.; Lenzen, M.; Lopez-Sendon, J.; Nihoyannopoulos, P.; Isla, L.P.; Schwehr, U.; Torraca, L.; Vachiery, J.L. Guidelines on the diagnosis and management of acute pulmonary embolism - The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur. Heart J., 2008, 29(18), 2276-2315.
62. Lev-Sagie, A.; Bar-Oz, B.; Salpeter, L.; Hochner-Celnikier, D.; Arad, I.; Nir, A.; Lev-Sagiel. Plasma concentrations of N-terminal pro-B-type natriuretic peptide in pregnant women near labor and during early puerperium. Clin. Chem., 2005, 51(10), 1909-1910.
63. Zatelli, M.C.; Torta, M.; Leon, A.; Ambrosio, M.R.; Gion, M.; Tomassetti, P.; De Braud, F.; Delle Fave, G.; Dogliotti, L.; Degli Uberti, E.C. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endoc.-Related Cancer, 2007, 14(2), 473-482.
64. Syversen, U.; Opsjon, S.L.; Stridsberg, M.; Sandvik, A.K.; Dimaline, R.; Tingulstad, S.; Arntzen, K.J.; Brenna, E.; Waldum, H.L. Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies. J. Clin. Endocrinol. Metabol., 1996, 81(12), 4470-4475.
65. Modlin, I.M.; Gustafsson, B.I.; Moss, S.F.; Pavel, M.; Tsolakis, A. V.; Kidd, M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol., 2010, 17(9), 2427-2443.
66. Sidhu, R.; Drew, K.; McAlindon, M.E.; Lobo, A.J.; Sanders, D.S. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and Inflammatory Bowel Disease (IBD): A shared model for pathogenesis? Inflamm. Bowel Dis., 2010, 16(3), 361-361.
67. Suminami, Y.; Nawata, S.; Kato, H. Biological role of SCC antigen. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 1998, 19(6), 488-93.
68. Orum, O.; Hansen, M.; Jensen, C.H.; Sorensen, H.A.; Jensen, L. B.;Horslev-Petersen, K.; Teisner, B., Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone, 1996, 19(2), 157-163.
69. Kauppila, S.; Tekay, A.; Risteli, L.; Koivisto, M.; Risteli, J. Type I and type III procollagen propeptides in amniotic fluid of normal pregnancies and in a case of mild osteogenesis imperfecta. Eur. J. Clin. Invest., 1998, 28(10), 831-837.
70. Leeming, D.J.; Larsen, D.V.; Zhang, C.; Hi, Y.; Veidal, S.S.; Nielsen, R.H.; Henriksen, K.; Zheng, Q.; Barkholt, V.; Riis, B.J.; Byrjalsen, I.; Qvist, P.; Karsdal, M.A. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP) - Assessment of corresponding epitopes. Clin. Biochem., 2010, 43(15), 1249-1256.
71. Koivula, M.K.; Risteli, L.; Risteli, J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin. Biochem., 2012, 45(12), 920-927.
72. Mock, P.; Frydman, R.; Bellet, D.; Chassin, D.; Bischof, P.; Campana, A.; Bidart, J.M. Expression of pro-EPIL peptides encoded by the insulin-like 4 (INSL4) gene in chromosomally abnormal pregnancies. J. Clin. Endocrinol. Metabol., 2000, 85(10), 3941-3944.
73. Bruni, L.; Luisi, S.; Ferretti, C.; Janneau, J.L.; Quadrifoglio, M.; Richon, S.; Dangles-Marie, V.; Bellet, D.; Petraglia, F. Changes in the maternal serum concentration of proearly placenta insulin-like growth factor peptides in normal vs abnormal pregnancy. Amer. J. Obstet. Gynecol., 2007, 197(6).
74. Sahu, D.K.; Panda, S.P.; Panda, S.; Das, P.; Meher, P.K.; Hazra, R. K.; Peatman, E.; Liu, Z.J. J.; Eknath, A.E.; Nandi, S. Identification of reproduction-related genes and SSR-markers through expressed sequence tags analysis of a monsoon breeding carp rohu, Labeo rohita (Hamilton). Gene, 2013, 524(1), 1-14.
75. Raffin-Sanson, M.L.; Ferre, F.; Coste, J.; Oliver, C.; Cabrol, D.; Bertagna, X. Pro-opiomelanocortin in human pregnancy: evolution of maternal plasma levels, concentrations in cord blood, amniotic fluid and at the feto-maternal interface. Europ. J. Endocrinol./ Europ. Fed. Endocrine Societ., 2000, 142(1), 53-59.
76. Cooper, E.S.; Greer, I.A.; Brooks, A.N. Placental proopiomelanocortin gene expression, adrenocorticotropin tissue concentrations, and immunostaining increase throughout gestation and are unaffected by prostaglandins, antiprogestins, or labor. J. Clin. Endocr. Metab., 1996, 81(12), 4462-4469.
77. Raffin-Sanson, M.L.; Ferre, F.; Coste, J.; Oliver, C.; Cabrol, D.; Bertagna, X. Pro-opiomelanocortin in human pregnancy: evolution of maternal plasma levels, concentrations in cord blood, amniotic fluid and at the feto-maternal interface. Europ. J. Endocrinol., 2000, 142(1), 53-59.
78. ElShafei, A.; Li, Y.H.; Hatem, A.; Moussa, A.S.; Ethan, V.; Krishnan, N.; Li, J.B.; Jones, J.S. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy. Prostate, 2013, 73(16), 1796-1802.
79. Olsson, A. Y.; Bjartell, A.; Lilja, H.; Lundwall, A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int. J. Cancer. 2005, 113(2), 290-297.
80. Melegos, D.N.; Yu, H.; Allen, L.C.; Diamandis, E.P. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin. Biochem., 1996, 29(6), 555-562.
81. Yu, H.; Diamandis, E.P. Prostate-specific antigen immunoreactivity in amniotic-fluid. Clin. Chem., 1995, 41(2), 204-210.
82. Kassanos, D.; Botsis, D.; Rizos, D.; Kontoravdis, A.; Sikiotis, K.; Phocas, I.; Sarandakou, A.; Creatsas, G. Tissue polypeptide specific antigen (TPS) throughout normal pregnancy. Anticancer Res., 2000, 20(3B), 2129-2131.
83. Inaba, N.; Fukasawa, I.; Okajima, Y.; Ota, Y.; Tanaka, K.; Matsui, H.; Iwasaki, H.; Sato, N.; Sudo, H.; Bjorklund, B. et al. Immunoradiometrical measurement of tissue polypeptide specific antigen (TPS) in normal, healthy, nonpregnant and pregnant Japanese women. AOFOG, 1993, 19(4), 459-66.
84. Sarandakou, A.; Malamitsi-Puchner, A.; Protonotariou, E.; Rigopoulou, U.; Papagianni, B.; Creatsas, G. Indicative markers of cell proliferation and apoptosis during the perinatal period. Amer. J. Perinatol., 2003, 20(6), 283-288.
85. Michel, P.E.; Crettaz, D.; Morier, P.; Heller, M.; Gallot, D.; Tissot, J.D.; Reymond, F.; Rossier, J.S. Proteome analysis of human plasma and amniotic fluid by Off-Gel (TM) isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis, 2006, 27(5-6), 1169-1181.
86. Rooney, I.A.; Morgan, B.P. Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 1992, 76 (4), 541-7.
87. Abele, R.; Tampe, R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology, (Bethesda) 2004, 19, 216-24.
88. Yamaguchi, Y.; Passeron, T.; Hoashi, T.; Watabe, H.; Rouzaud, F.;Yasumoto, K.; Hara, T.; Tohyama, C.; Katayama, I.; Miki, T.;Hearing, V. J. Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in keratinocytes. FASEB, 2008, 22 (4), 1009-20.
89. Kierszenbaum, A.L. Polycystins: what polycystic kidney disease tells us about sperm. Molecul. Reproduct. Develop., 2004, 67(4), 385-8.
90. Krupa, F.G.; Faltin, D.; Cecatti, J.G.; Surita, F.G.; Souza, J.P. Predictors of preterm birth. Int. J. Gynaecol. Obstet., 2006, 94(1), 5-11.
91. Yurchenco, P.D.; Amenta, P.S.; Patton, B.L. Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol., 2004, 22(7), 521-38.
92. Bera, T.K.; Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Molecul. Cellul. Biol.,2000, 20(8), 2902-6.
93. Conlon, I.; Raff, M. Size control in animal development. Cell, 1999, 96(2), 235-44.
94. Mizejewski, G.J. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstetrical Gynecologic. Survey, 2003, 58(12), 804-26.
95. Demir, N.; Celiloglu, M.; Thomassen, P.A.; Onvural, A.; Erten, O. Maternal, fetal and amniotic fluid prolactin levels in term and post-term pregnancies. Acta Obstet. Gynecol. Scand., 1993, 72(3), 218-20.
96. Ognibene, A.; Ciuti, R.; Tozzi, P.; Messeri, G. Maternal serum superoxide dismutase (SOD): a possible marker for screening Down syndrome affected pregnancies. Prenatal Diagnos., 1999, 19(11), 1058-60.
97. Porstmann, T.; Wietschke, R.; Cobet, G.; Lorenz, K.; Grunow, R.;Jahn, S.; Bollmann, R.; Stamminger, G.; von Baehr, R. Immunochemical quantification of Cu/Zn superoxide dismutase in prenatal diagnosis of Down's syndrome. Human Genet., 1990, 85(3), 362-6.
98. Monaco, H. L., The transthyretin-retinol-binding protein complex. Biochimica et Biophysic. Acta, 2000, 1482(1-2), 65-72.
99. Ilhan, N.; Ilhan, N.; Simsek, M. The changes of trace elements, malondialdehyde levels and superoxide dismutase activities in pregnancy with or without preeclampsia. Clin. Biochem., 2002, 35(5), 393-397.
100. Perrone, S.; Longini, M.; Bellieni, C.V.; Centini, G.; Kenanidis, A.;De Marco, L.; Petraglia, F.; Buonocore, G. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin. Biochem., 2007, 40(3-4), 177-180.
101. Gilad, S.; Meiri, E.; Yogev, Y.; Benjamin, S.; Lebanony, D.;Yerushalmi, N.; Benjamin, H.; Kushnir, M.; Cholakh, H.; Melamed, N.; Bentwich, Z.; Hod, M.; Goren, Y.; Chajut, A. Serum MicroRNAs Are Promising Novel Biomarkers. Plos One, 2008, 3(9).
102. Thery, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol., 2009, 9(8), 581-593.
103. Cocucci, E.; Racchetti, G.; Meldolesi, J. Shedding microvesicles: artefacts no more. Trends Cell Biol., 2009, 19(2), 43-51.
104. Simons, M.; Raposo, G. Exosomes--vesicular carriers for intercellular communication. Curr. Opin. Cell Biol., 2009, 21(4), 575-81.
105. De Guire, V.; Robitaille, R.; Tetreault, N.; Guerin, R.; Menard, C.;Bambace, N.; Sapieha, P. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: Promises and challenges. Clin. Biochem., 2013, 46(10-11), 846-860.
106. Weber, J.A.; Baxter, D.H.; Zhang, S.L.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The MicroRNA Spectrum in 12 Body Fluids. Clin. Chem., 2010, 56(11), 1733-1741.
107. Choi, D.S.; Yang, J.S.; Choi, E.J.; Jang, S.C.; Park, S.; Kim, O.Y.;Hwang, D.; Kim, K.P.; Kim, Y.K.; Kim, S.; Gho, Y.S. The Protein Interaction Network of Extracellular Vesicles Derived from Human Colorectal Cancer Cells. J. Proteome Res., 2012, 11(2), 1144-1151.
108. Raimondo, F.; Morosi, L.; Chinello, C.; Magni, F.; Pitto, M. Advances in embranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics, 2011, 11(4), 709-720.
109. Gaucherand, P.; Salle, B.; Sergeant, P.; Guibaud, S.; Brun, J.; Bizollon, C.A.; Rudigoz, R.C. Comparative study of three vaginal markers of the premature rupture of membranes - Insulin like growth factor binding protein 1 diamine-oxidase pH. Acta Obstet. Gyn. Scan., 1997, 76 (6), 536-540.
110. Ye, F.; Cayre, Y.E.; Thang, M.N. Evidence for a novel RasGAP-associated protein of 105 kDa in both mature trophoblasts and differentiating choriocarcinoma cells. Biochem. Bioph. Res. Co., 1999, 263(2), 523-527.
111. Ind, T.E.; Iles, R.K.; Wathen, N.C.; Carvalho, C.; Campbell, J.; Chard, T. Second trimester amniotic fluid placental alkaline phosphatase levels are low in Down's syndrome but not in other fetal abnormalities. Early Human Develop., 1994, 37(1), 39-44.
112. Lorenzen, J.A.; Bonacci, B.B.; Palmer, R.E.; Wells, C.; Zhang, J.; Haber, D.A.; Goldstein, A. M.; Mayer, A.N. Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium. Gene Expr. Patterns, 2005, 6(1), 45-56.
113. Subra, C.; Laulagnier, K.; Perret, B.; Record, M., Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie, 2007, 89(2), 205-212.
114. Kooijmans, S.A.A.; Vader, P.; van Dommelen, S.M.; van Solinge, W.W.; Schiffelers, R.M. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomed., 2012, 7, 1525-1541.
115. Abi-Rizk, G.; Besson, F., Interactions of Triton X-100 with sphingomyelin and phosphatidylcholine monolayers: Influence of the cholesterol content. Colloid Surf. B., 2008, 66(2), 163-167.
116. Ramstedt, B.; Slotte, J.P. Membrane properties of sphingomyelins. Febs. Lett., 2002, 531(1), 33-37.
117. Needham, D.; Nunn, R.S. Elastic-Deformation and Failure of Lipid Bilayer-Membranes Containing Cholesterol. Biophys. J., 1990, 58(4), 997-1009.
118. Kim, C.W.; Lee, H.M.; Lee, T. H.; Kang, C.H.; Kleinman, H.K.; Gho, Y.S. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res., 2002, 62 (21), 6312-6317.
119. Subra, C.; Grand, D.; Laulagnier, K.; Stella, A.; Lambeau, G.; Paillasse, M.; De Medina, P.; Monsarrat, B.; Perret, B.; Silvente-Poirot, S.; Poirot, M.; Record, M. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J. Lipid Res., 2010, 51(8), 2105-2120.
120. Ratajczak, J.; Miekus, K.; Kucia, M.; Zhang, J.; Reca, R.; Dvorak, P.; Ratajczak, M.Z. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia, 2006, 20(5), 847-56.
121. Deregibus, M.C.; Cantaluppi, V.; Calogero, R.; Lo Iacono, M.; Tetta, C.; Biancone, L.; Bruno, S.; Bussolati, B.; Camussi, G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood, 2007, 110(7), 2440-2448.
122. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D.H.; Gainche, L.; Sena-Esteves, M.; Curry, W. T., Jr.; Carter, B.S.; Krichevsky, A.M.; Breakefield, X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biol., 2008, 10(12), 1470-1476.
123. Hong, B.S.; Cho, J.H.; Kim, H.; Choi, E.J.; Rho, S.; Kim, J.; Kim, J.H.; Choi, D.S.; Kim, Y.K.; Hwang, D.; Gho, Y.S. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genom., 2009, 10, 556.
124. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J.J.; Lotvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biol., 2007, 9(6), 654-659.
125. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C.M. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Nat. Acad. Sci. USA, 2002, 99(24), 15524-15529.
126. Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggins, A.P.; Pulford, K.; Banham, A.H.; Pezzella, F.; Boultwood, J.; Wainscoat, J.S.; Hatton, C.S.R.; Harris, A.L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Brit. J. Haematol., 2008, 141(5), 672-675.
127. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Nat. Acad. Sci. USA, 2008, 105(30), 10513-10518.
128. Wang, T.; Zhou, R.; Zhang, L.; Wang, Y.Y.; Song, C. P.; Lin, W.; Niu, X.Y.; Lin, Y.; Hu, H. Z. Proteins in leaked amniotic fluid as biomarkers diagnostic for prelabor rupture of membranes. Proteom. Clin. Appl., 2011, 5(7-8), 415-421.